Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 980-986

  Garcia Contreras, L ^a   Sethuraman, V ^a   Kazantseva, M ^a   Godfrey, V ^a   Hickey, A J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Aerosols; Lung deposition; Nebulized suspensions; PLGA

Indexed keywords

MICROSPHERE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; GUINEA PIG; HISTOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG; MALE; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; ORGAN SIZE; SPLEEN; TUBERCULOSIS;

ADMINISTRATION, INHALATION; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; DRUG DELIVERY SYSTEMS; GUINEA PIGS; LUNG; MALE; MICROSPHERES; MYCOBACTERIUM TUBERCULOSIS; ORGAN SIZE; RIFAMPIN; SPLEEN; TUBERCULOSIS;

EID: 34547627972     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl369     Document Type: Article

References (45)

1. Manca C, Tsenova L, Barry C et al. Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol 1999; 162: 6740-6.
2. World Health Organization. Tuberculosis fact sheet. http://www.who.int/inf-fs/en/fact104.html (2005, date last accessed).
3. Zierski E, Bek E. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study. Tubercle 1980; 61: 41-9.
4. Peloquin C, Berning SE. Infection caused by Mycobacterium tuberculosis. Ann Pharmacother 1994; 28: 72-84.
5. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 4: 327-41.
6. Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clin Lab Med 1996; 16: 717-29.
7. Ferin J, Oberdörster G. Translocation of particles from pulmonary alveoli into the interstitium. J Aerosol Med 1992; 5: 179-87.
8. Gillett NA, Harmsen AG, Stegelmeir B. Translocation of particles by macrophages from lung to lymph nodes in rats. J Aerosol Med 1989; 2: 29-37.
9. Lehnert BE, Toeves KE, Sebring RJ et al. Failure of a simple model of alveolar macrophage-mediated particle clearance to depict particle-alveolar macrophage relationship during early alveolar phase clearance. J Aerosol Med 1991; 4: 41-56.
10. Mueller HL, Robinson B, Muggenburg BA et al. Particle distribution in lung and lymph node tissues of rats and dogs and the migration of particle-containing alveolar cells in vitro. J Toxicol Environ Health 1990; 30: 141-65.
11. Suarez S, O'Hara P, Kazantseva M et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrobial Chemother 2001; 48: 431-4.
12. Suarez S, O'Hara P, Kazantseva M et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 2001; 18 1315-19.
13. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28: 5-24.
14. Baker RW. Controlled Release of Biologically Active Agents. New York: Wiley, 1987.
15. Roseman TJ, Mansdorf SZ, eds. Controlled Release Deliverly Systems New York: Dekker, 1983.
16. Martin A. Physical Pharmacy, 4th edn. New York: Lippincott Williams & Wilkins, 1993.
17. O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization. Pharm Res 2000; 17: 955-61.
18. Aerosols. In: United States Pharmacopeia. Toronto: Webcom Limited, 2006; 2617-36.
19. Wiegeshaus EH, McMurray DN, Grover AA et al. Host-parasite relationships in experimental airborne tuberculosis. 3. Relevance of microbial enumeration to acquired resistance in guinea pigs. Am Rev Respir Dis 1970; 102: 422-8.
20. Mainali ES, McMurray DN. Protein deficiency induces alterations in the distribution of T-cell subsets in experimental pulmonary tuberculosis. Infect Immun 1998; 66: 927-31.
21. Demidov SV, Miasnikov VG, Chernushenko EF et al. Effect of thymus preparations and anti-tuberculosis agents on immunologic reactivity and the course of the tuberculosis process in experimental animals. Probl Tuberk 1991; 52-4.
22. Reference deleted.
23. Devi TI, Gupta RP, Dhawan RK et al. Chemotherapy of experimental tuberculosis with N-(2-naphthyl)glycine hydrazide dihydrochloride: part I. Acute toxity and effect on wet weight, dry weight, glycogen and total lipids of organs. Indian J Clin Biochem 1988; 3: 37-44.
24. Drandarska I, Kussovski V, Nikolaeva S et al. Combined immunomodulating effects of BCG and Lentinan after intranasal application in guinea pigs. Int Immunopharmacol 2005; 5: 795-803.
25. Jiang S, Zhu D, Jiang Y et al. Therapeutic effect of eukaryotic expression plasmid psIL-12 on murine infection with Mycobacterium tuberculosis. Zhonghua Weishengwuxue He Mianyixue Zazhi 2005; 24 373-6.
26. Niu X, Liu C, Li Y et al. Therapeutic action of Luolining capsules on tuberculotic guinea pigs. Zhongguo Yaoke Daxue Xuebao 1998; 29: 142-4.
27. Heinrich U, Fuhst R, Rittinghausen S et al. Chronic inhalation exposure of Wistar rats and two different strains of mice to diesel engine exhaust, carbon black, and titanium dioxide. Inhalation Toxicol 1995; 7: 533-56.
28. Henderson RF, Pickrell JA, Jones RK et al. Response of rodents to inhaled diluted diesel exhaust: Biochemical and cytological changes in bronchoalveolar lavage fluid and in lung tissue. Fundam Appl Toxicol 1988; 11: 546-67.
29. Mauderly JL. Noncancer pulmonary effects of chronic inhalation exposure of animals to solid particles. In: Mohr U, Dungworth DL, Mauderly JL, eds. Toxic and Carcinogenic Effects of Solid Particles in the Respiratory Tract: Proceedings of the Fourth International Inhalation Symposium. Washington, DC: International Life Science Institute Press, 1993; 43-55.
30. Mauderly JL, Bice DE, Cheng YS et al. Influence of preexisting pulmonary emphysema on susceptibility of rats to diesel exhaust. Am Rev Respir Dis 1990; 141: 1333-41.
31. Nikula KJ, Snipes MB, Barr EB et al. Comparative pulmonary toxicities and carcinogenicities of chronically inhaled diesel exhaust and carbon black in F344 rats. Fundam Appl Toxicol 1995; 25: 80-94.
32. Pepelko WE. Effects of 28 days exposure to diesel engine emissions in rats. Environmental Res 1982; 27: 16-23.
33. Venkatesan N, Punithavathi V, Chandrakasan G. Curcumin protects bleomycin-induced lung injury in rats. Life Sci 1997; 61: PL51-8.
34. Clottens FL, Verbeken EK, Demedts M et al. Pulmonary toxicity of components of textile paint linked to the Ardystil syndrome: intratracheal administration in hamsters. Occup Environ Med 1997; 54: 376-87.
35. García-Contreras L, Cooney DJ, Kazantseva M et al. Uptake of biodegradable microspheres by guinea pig alveolar macrophages. J Aerosol Med 2003; 16: 218.
36. McMurray D. Guinea pig model of tuberculosis. In: Bloom B, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: ASM Press, 1994; 135-48.
37. Garcia-Contreras L, Hickey AJ. Pharmacokinetics of aerosolized rifampicin in the guinea pig. In: Dalby RN, Byron PR, Peart J et al, eds. Respiratory Drug Delivery VIII. Raleigh, NC: Davis Horwood International Publishing, Ltd, 2002; 699-701.
38. Smith SJ, Bernstein JA. Therapeutics uses of lung aerosols. In: Hickey AJ, ed. Inhalation Aerosols. Physical and biological basis for therapy. New York: Marcel Dekker Inc., 1996; 233-69.
39. García-Contreras L, Cooney D, Hickey A. Validation of the use of the guinea pig model as a tool to evaluate the efficacy of novel formulations and treatments for tuberculosis. AAPS J 2005; 7 Suppl 2: Abstract W4177. Available from: http://www.aapsj.org/.
40. Tsapis N, Bennett D, Jackson B et al. Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 2002; 99: 12001-5.
41. Tsapis N, Bennett D, O'Driscoll K et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis (Edinb) 2003; 83: 379-85.
42. Sharma R, Saxena D, Dwivedi AK et al. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001; 18: 1405-10.
43. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005; 85: 227-34.
44. Pandey R, Sharma A, Zahoor A et al. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrobial Chemother 2003; 52 981-6.
45. Sharma A, Pandey R, Sharma S et al. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents 2004; 24: 599-604.